NCT05438459View on ClinicalTrials.gov

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 8, 2027

Conditions
Gastric CancerPancreatic Cancer
Interventions
BIOLOGICAL

Phase I part

Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.

BIOLOGICAL

Phase II part

Randomized into group of administration of GAIA-102 as a monotherapy or GAIA-102 or pembrolizumab in combination, group of standard treatment

Trial Locations (1)

812-8582

RECRUITING

Kyushu University Hospital, Fukuoka

Sponsors

Collaborators (1)

GAIA BioMedicine Inc.
All Listed Sponsors
collaborator

GAIA BioMedicine Inc.

INDUSTRY

collaborator

Toho University - Omori Medical Center

UNKNOWN

collaborator

Jichi Medical University

OTHER

collaborator

Kindai University Hospital

UNKNOWN

collaborator

Teikyo University Hospital

UNKNOWN

collaborator

Kansai Medical University Hospital

UNKNOWN

collaborator

Kyushu Cancer Center

UNKNOWN

lead

Kyushu University

OTHER